NANOBIOTIX (EPA:NANO) | WebDisclosure

Basculer en Français

9480	Companies
185543	Keywords
117939	Articles
99384	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 10/01/2025 at 22:15, 2 months 3 days ago

NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage
Nanobiotix annonce les premières données de phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage. Taux de contrôle de la maladie de 85% et taux de réponse objective de 69%

NANOBIOTIX Phase 1 JNJ-1900 ASTRO Cancer De L’œsophage
PRESS RELEASE

published on 10/01/2025 at 22:15, 2 months 3 days ago

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Nanobiotix announces first data from Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with esophageal cancer. Results presented at ASTRO 2025 Annual Meeting

NANOBIOTIX Phase 1 Study JNJ-1900 Esophageal Cancer ASTRO
PRESS RELEASE

published on 09/30/2025 at 22:27, 2 months 4 days ago

RAPPORT FINANCIER SEMESTRIEL
BRIEF

published on 09/30/2025 at 22:20, 2 months 4 days ago

Nanobiotix : Bilan financier et avancées cliniques au 1er semestre 2025

Résultats Financiers Biotechnologie NANOBIOTIX Johnson & Johnson JNJ-1900
BRIEF

published on 09/30/2025 at 22:20, 2 months 4 days ago

Nanobiotix: Financial results and clinical progress in the first half of 2025

Financial Results Biotechnology NANOBIOTIX Johnson & Johnson JNJ-1900
PRESS RELEASE

published on 09/30/2025 at 22:15, 2 months 4 days ago

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
Nanobiotix provides business update & reports 2025 half year financial results. Highlights clinical development program & financial performance

Financial Results Financial Performance Business Update Clinical Development NANOBIOTIX
PRESS RELEASE

published on 09/30/2025 at 22:15, 2 months 4 days ago

NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025
Nanobiotix fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025, marqué par le développement clinique de JNJ-1900 et une gestion financière rigoureuse

Résultats Financiers Développement Clinique Gestion Financière NANOBIOTIX JNJ-1900
BRIEF

published on 09/30/2025 at 00:35, 2 months 5 days ago

NANOBIOTIX Reports Promising Phase 1 Results for JNJ-1900 (NBTXR3) in R/M-HNSCC

Phase 1 Trial NANOBIOTIX Clinical Study Results R/M-HNSCC JNJ-1900 (NBTXR3)
BRIEF

published on 09/30/2025 at 00:35, 2 months 5 days ago

NANOBIOTIX annonce des résultats prometteurs de phase 1 pour JNJ-1900 (NBTXR3) dans le traitement du carcinome épidermoïde œsophagien (HNSCC) métastatique (R/M)

NANOBIOTIX Essai De Phase 1 Résultats Des Études Cliniques R/M-HNSCC JNJ-1900 (NBTXR3)
PRESS RELEASE

published on 09/30/2025 at 00:30, 2 months 5 days ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Nanobiotix announces updated phase 1 results supporting JNJ-1900 plus anti-PD-1 as a new option in R/M-HNSCC. Promising local and systemic responses presented at ASTRO 2025

NANOBIOTIX Anti-PD-1 JNJ-1900 R/M-HNSCC ASTRO 2025

Accesswire

Published on 12/05/2025 at 20:25, 12 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 22 minutes ago

When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 47 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 1 hour 17 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 1 hour 52 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 1 hour 39 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 2 hours 10 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 2 hours 21 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 2 hours 45 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 2 hours 50 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 3 hours 19 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 3 hours 19 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 26 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 26 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 6 hours 38 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE